Thetis Pharmaceuticals
PrivateLast Round
Debt
Jan 9, 2025
Total Funding Raised
$17.4M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
Thetis Pharmaceuticals is a clinical-stage pharmaceutical company that develops first-in-class oral Resolvin E1 therapeutics for inflammatory bowel disease and solid tumors.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Thetis Pharmaceuticals Comparables
Compare Thetis Pharmaceuticals with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Landos Biopharma | 77% | |
| Zymeworks Inc. | 72% | |
| Surrozen | 69% |
Thetis Pharmaceuticals Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Debt | Jan 9, 2025 | ||||
| Debt | Apr 4, 2022 | ||||
| Grant | Jul 12, 2021 | ||||
| Grant | Nov 19, 2019 | ||||
| Grant | Aug 1, 2018 | ||||
Grant | Nov 16, 2017 |
Key People
Founding team and executive leadership
Thetis Pharmaceuticals Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Connecticut Innovations | Seed |
| NIH RADx | Grant |
| Helmsley Charitable Trust | Debt |
| National Institute of Diabetes and Digestive and Kidney Diseases | Grant |
| Stonehenge Growth Capital | Seed |
| Crohn's & Colitis Foundation | Grant |
| Kenneth Rainin Foundation | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 11, 2026
Monthly visitors increased 41% MoM.
- Aug 21, 2026
Monthly visitors grew 192% MoM, from 423 to 1.2K.
Recent news
Latest coverage and updates
- receives_financingSep 17, 2026
Thetis Pharmaceuticals LLC receives a $1M SBIR Commercialization Readiness Pilot award from NIDDK of the NIH on Sep 17th '26 in Connecticut to fund GLP nonclinical toxicology studies advancing oral TP-317 beyond its Phase 1b ulcerative colitis trial.
Thetis Pharmaceuticals Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Thetis Pharmaceuticals's valuation, stock price, and market status.
Is Thetis Pharmaceuticals a public or private company?
Thetis Pharmaceuticals is a private company.
What is the current stock price of Thetis Pharmaceuticals?
Thetis Pharmaceuticals is a private company, so its shares have no public market price. Caplight tracks Thetis Pharmaceuticals's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Thetis Pharmaceuticals worth (valuation)?
Valuation information for Thetis Pharmaceuticals is not publicly available.
Can I buy Thetis Pharmaceuticals stock?
Thetis Pharmaceuticals shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Thetis Pharmaceuticals's last funding round?
Thetis Pharmaceuticals's most recent funding round was Debt on January 9, 2025.
Who are the main investors in Thetis Pharmaceuticals?
Key investors in Thetis Pharmaceuticals include Connecticut Innovations, NIH RADx, Helmsley Charitable Trust, Crohn's & Colitis Foundation, Kenneth Rainin Foundation.
Will Thetis Pharmaceuticals IPO soon?
No public IPO plans have been announced for Thetis Pharmaceuticals.
How can I track Thetis Pharmaceuticals secondary market activity?
Caplight tracks bids, offers, and trades in Thetis Pharmaceuticals's shares on secondary markets.